Cdk1 is sufficient to drive the mammalian cell cycle
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Self-citationCyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Self-citationMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Self-citationRane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Self-citationBerthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
Cyclin E Ablation in the Mouse
Geng, Y., Yu, Q., Sicinska, E., Das, M., Schneider, J. E., Bhattacharya, S., Rideout, W. M., Bronson, R. T., Gardner, H., & Sicinski, P. (2003) · Cell · doi:10.1016/s0092-8674(03)00645-7 · Cited by 660
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Multiple levels of cyclin specificity in cell-cycle control
Bloom, J., & Cross, F. R. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2105 · Cited by 503
Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases
Zarkowska, T., & Mittnacht, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12738 · Cited by 493
Cited by
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Self-citationCell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Self-citationPaul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
Puente, B. N., Kimura, W., Muralidhar, S. A., Moon, J., Amatruda, J. F., Phelps, K. L., Grinsfelder, D., Rothermel, B. A., Chen, R., Garcia, J. A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.032 · Cited by 909
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Genetic compensation: A phenomenon in search of mechanisms
El-Brolosy, M. A., & Stainier, D. Y. R. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006780 · Cited by 829
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
Satyanarayana, A., & Kaldis, P. (2009) · Oncogene · doi:10.1038/onc.2009.170 · Cited by 774
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
Cyclin-dependent kinases and cell-cycle transitions: does one fit all?
Hochegger, H., Takeda, S., & Hunt, T. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2510 · Cited by 603
Endoreplication: polyploidy with purpose
Lee, H. O., Davidson, J. M., & Duronio, R. J. (2009) · Genes & Development · doi:10.1101/gad.1829209 · Cited by 590
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
“We have assessed the relative contribution of individual interphase Cdks, Cdk2, Cdk4, and Cdk6, to the proliferative and oncogenic properties conveyed by expression of an endogenous K-RasG12V oncogene.”
BackgroundInfluentialSelf-citationDriving the cell cycle with a minimal CDK control network
Coudreuse, D., & Nurse, P. (2010) · Nature · doi:10.1038/nature09543 · Cited by 396
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Self-citationDiril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385
“Constitutive gene disruption mutations in the Cdk1 locus have been reported, but neither of these approaches yielded homozygous Cdk1 cells or tissues for further analysis (16, 17).”
BackgroundInhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
“5) (Santamaria et al., 2007).”
Cell cycle control across the eukaryotic kingdom
Harashima, H., Dissmeyer, N., & Schnittger, A. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.03.002 · Cited by 374
Endocycles: a recurrent evolutionary innovation for post-mitotic cell growth
Edgar, B. A., Zielke, N., & Gutierrez, C. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3756 · Cited by 366
Targeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
CDK Substrate Phosphorylation and Ordering the Cell Cycle
Swaffer, M. P., Jones, A. W., Flynn, H. R., Snijders, A. P., & Nurse, P. (2016) · Cell · doi:10.1016/j.cell.2016.11.034 · Cited by 349
Establishment of human papillomavirus infection requires cell cycle progression
Pyeon, D., Pearce, S. M., Lank, S. M., Ahlquist, P., & Lambert, P. F. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000318 · Cited by 348
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer
Petralia, F., Tignor, N., Reva, B., Koptyra, M., Chowdhury, S., Rykunov, D., Krek, A., Ma, W., Zhu, Y., Ji, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.044 · Cited by 317
“CDK1 and CDK2, essential cyclin-dependent kinases promoting the G2M transition and regulating G1 progression and the G1-S transition (Santamarı́a et al., 2007), were elevated in more proliferative tumors, including ATRT, MB, HGG, and EP based on global abundance and kinase activity (Figures 4A and S4B; Table S4), the…”
BackgroundCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Cell cycle regulation and anticancer drug discovery
Jingwen, B., Yaochen, L., & Guojun, Z. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2017.0033 · Cited by 302
Regulation of cell proliferation by hypoxia-inducible factors
Hubbi, M. E., & Semenza, G. L. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00279.2015 · Cited by 300
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Actin cytoskeleton dynamics and the cell division cycle
Heng, Y.-W., & Koh, C.-G. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.04.007 · Cited by 283
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance
Xie, B., Wang, S., Jiang, N., & Li, J. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.11.019 · Cited by 261
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Herschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
MYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
“In contrast to panCDK inhibitors, which exhibit general toxicity, CDK4/6-specific inhibitors such as PD0332991 are well tolerated by patients, possibly because of the observation that CDK4/6 are dispensable in normal, untransformed cells (13).”
BackgroundViatour, P., Somervaille, T. C., Venkatasubrahmanyam, S., Kogan, S., McLaughlin, M. E., Weissman, I. L., Butte, A. J., Passegué, E., & Sage, J. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.009 · Cited by 178
“This analysis of the phenotype of Rb family TKO HSCs and hematopoietic progenitors complements recent in vivo studies with mice mutant for families of mammalian genes, especially cell-cycle regulators (Geng et al., 2003; Kozar et al., 2004; Krimpenfort et al., 2007; Santamaria et al., 2007).”
G1 to S phase cell cycle transition in somatic and embryonic stem cells
Neganova, I., & Lako, M. (2008) · Journal of Anatomy · doi:10.1111/j.1469-7580.2008.00931.x · Cited by 170
“Moreover, they show that in the absence of interphase Cdks, Cdk1 can execute all the events that are required to drive cell division (Santamaria et al. 2007).”
BackgroundWood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J. A., Noble, M. E. M., & Martin, M. P. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.015 · Cited by 168
“This difference may underlie the essential cell-cycle role of CDK1, which can bind a sufficient set of cyclins to drive all phases of the cell cycle (Santamaria et al., 2007), and can phosphorylate suboptimal model substrates in a reconstituted system (Brown et al.”
BackgroundCircadian Clock, Cell Division, and Cancer: From Molecules to Organism
Shostak, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040873 · Cited by 167
“Similar to yeast, mammalian CDK1 is able to bind all types of cyclins and maintain proliferation in embryos until mid-gestation [35].”
BackgroundCell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors
Bendris, N., Lemmers, B., & Blanchard, J. M. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998085 · Cited by 166
Linking a cell-division gene and a suicide gene to define and improve cell therapy safety
Liang, Q., Monetti, C., Shutova, M. V., Neely, E. J., Hacibekiroglu, S., Yang, H., Kim, C., Zhang, P., Li, C., Nagy, K., et al. (2018) · Nature · doi:10.1038/s41586-018-0733-7 · Cited by 158
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1009 · Cited by 150
Metabolic Remodeling during Liver Regeneration
Caldez, M. J., Van Hul, N., Koh, H. W. L., Teo, X. Q., Fan, J. J., Tan, P. Y., Dewhurst, M. R., Too, P. G., Talib, S. Z. A., Chiang, B. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.09.020 · Cited by 133
Cdk2 is required for p53-independent G2/M checkpoint control
Chung, J. H., & Bunz, F. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000863 · Cited by 105
“showed that Cdk2, Cdk4 and Cdk6 are dispensable for cell cycle progression. Cdk1 can bind D-, E-, and A-type cyclins and functionally substitute for the non-essential Cdks”
BackgroundCHK1 as a therapeutic target to bypass chemoresistance in AML
David, L., Fernandez-Vidal, A., Bertoli, S., Grgurevic, S., Lepage, B., Deshaies, D., Prade, N., Cartel, M., Larrue, C., Sarry, J.-E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac9704 · Cited by 76
WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity
Elbæk, C. R., Petrosius, V., Benada, J., Erichsen, L., Damgaard, R. B., & Sørensen, C. S. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110261 · Cited by 64
Cdc2: A monopotent or pluripotent CDK?
Hu, X., & Moscinski, L. C. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00753.x · Cited by 69
Qi, Q.-R., Zhao, X.-Y., Zuo, R.-J., Wang, T.-S., Gu, X.-W., Liu, J.-L., & Yang, Z.-M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1033593 · Cited by 58
Bichet, M. C., Adderley, J., Avellaneda-Franco, L., Magnin-Bougma, I., Torriero-Smith, N., Gearing, L. J., Deffrasnes, C., David, C., Pepin, G., Gantier, M. P., et al. (2023) · PLOS Biology · doi:10.1371/journal.pbio.3002341 · Cited by 47
“CDK1 is known to be at the center of all the control checkpoints for the cell cycle and its activation is required for cells to move between cell cycle phases [55].”
BackgroundLoss of hepatocyte cell division leads to liver inflammation and fibrosis
Dewhurst, M. R., Ow, J. R., Zafer, G., van Hul, N. K. M., Wollmann, H., Bisteau, X., Brough, D., Choi, H., & Kaldis, P. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1009084 · Cited by 42
“CDK1 drives mitosis in eukaryotic cells and is an essential gene in the mouse [15, 17].”
BackgroundCyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Tan, T. C. J., Kelly, V., Zou, X., Wright, D., Ly, T., & Zamoyska, R. (2022) · Nature Communications · doi:10.1038/s41467-022-35252-y · Cited by 30
(2021) · doi:10.1101/2021.06.25.449879 · Cited by 30
Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.03.006 · Cited by 23
Mapping the invisible chromatin transactions of prophase chromosome remodeling
Samejima, I., Spanos, C., Samejima, K., Rappsilber, J., Kustatscher, G., & Earnshaw, W. C. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.039 · Cited by 21
Ying, L., Yan, F., Williams, B. R., Xu, P., Li, X., Zhao, Y., Hu, Y., Wang, Y., Xu, D., & Dai, J. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12854 · Cited by 20
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Metadata
- Authors
- Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M.
- Venue
- Nature
- Published
- 2007-08-16
- Volume
- 448
- Issue
- 7155
- Pages
- 811-815
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132066963
- Cited by
- 1,114
- References
- 24
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.